Lacosamide vs Topiramate — Cost, Coverage & Plan Comparison

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1

Drug 2

Drug 3 (optional)

Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed

Compare across

11 dimensions

Anticonvulsant

Lacosamide

Brand: MOTPOLY XR

First FDA approval: 2009-05-26

Anticonvulsant

Topiramate

Brand: Eprontia

First FDA approval: 1997-01-01

Lowest NADACAcquisition cost floor across all NDCs

$0.095Per unit

$0.026Per unit

Average NADACAcross all dosage forms and strengths

$2.54Up to $21.31

$4.58Up to $43.72

Generic manufacturersActive ANDA holders — FDA Orange Book

2871 total ANDAs filed

23116 total ANDAs filed

Annualized Part D spendCY2024 — CMS Part D Spending Dashboard

$252.2MFull year

$193.8MFull year

Part D claims (CY24)Total fills, all strengths

1.4M243K beneficiaries

5.1M1.3M beneficiaries

Avg cost per claimCalculated: total spend ÷ total claims

$174Per claim, all NDCs

$38Per claim, all NDCs

Part D plans surveyed2026 plan year — CMS Formulary file

329Across CMS plan year

Prior-authorization frictionPlan-NDC pairs requiring PA

12Minimal friction

373Substantial friction

Step therapy appliedPlan-NDC pairs requiring step therapy

7Limited friction

56Limited friction

FDA shortage statusLive cross-reference vs FDA Drug Shortage Database

NoneClear

DiscontinuedSee drug profile

Generic availableFDA Orange Book

Yes28 manufacturers

Yes23 manufacturers